Publications by authors named "D T Capper"
Isocitrate dehydrogenase (IDH)-mutant gliomas, comprising both astrocytomas and oligodendrogliomas, represent a distinct group of tumors that pose an interdisciplinary challenge. Addressing the needs of affected patients requires close collaboration among various disciplines, including neuropathology, neuroradiology, neurosurgery, radiation oncology, neurology, medical oncology, and other relevant specialties when necessary. Interdisciplinary tumor boards are central in determining the ideal diagnostic and therapeutic strategies for these patients.
View Article and Find Full Text PDFArticle Synopsis
- IDH-mutant gliomas are the most common malignant brain tumors in young adults, causing significant challenges for patients, including cognitive deficits and high mortality due to tumor progression.
- Current treatments like surgery, radiation, and chemotherapy enhance survival but can have negative impacts on cognitive function and quality of life.
- The recent FDA approval of vorasidenib, a drug targeting mutant IDH1/2 proteins, represents a promising new approach, with ongoing trials exploring its use alongside other therapies for better patient outcomes.
Background: Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the CNS. They are not classified as a separate tumor type in the 2021 WHO classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on the role of Thyroid Transcription Factor-1 (TTF-1) in lung adenocarcinoma (LUAD) brain metastases, specifically its predictive value and relationship with patient outcomes.
- Researchers analyzed data from 245 patients who had brain metastases, looking at factors like tumor volume and survival rates based on TTF-1 expression status.
- Results indicate that TTF-1 negative patients had larger tumors, higher proliferation rates, and worse survival outcomes, suggesting that TTF-1 negativity signifies a more aggressive form of the disease, warranting further study on its underlying mechanisms.
Meningiomas are the most common primary intracranial tumors of adults. For meningiomas that progress or recur despite surgical resection and radiotherapy, additional treatment options are limited due to lack of proven efficacy. Meningiomas show recurring molecular aberrations, which may serve as predictive markers for systemic pharmacotherapies with targeted drugs or immunotherapy, radiotherapy or radioligand therapy.
View Article and Find Full Text PDF